|
|
|
| Efficacy of Evolocumab Combined with Atorvastatin in the Treatment of Symptomatic Intracranial Atherosclerotic Stenosis |
| MAO Zhenya1, CHEN Jiansu2 |
1. Department of Pharmacy, Jiangsu Provincial People's Hospital, Nanjing Jiangsu 210000;
2. Department of Cardiovascular and Vascular Surgery,the Fourth Affiliated Hospital of Nanjing Medical University,Nanjing Jiangsu 210000 |
|
|
|
|
Abstract 【Objective】 To investigate the efficacy of evolocumab combined with atorvastatin in the treatment of patients with symptomatic intracranial atherosclerotic stenosis (ICAS). 【Methods】 A total of 116 patients with symptomatic ICAS were randomly divided into the control group and the observation group, with 58 cases in each group. The control group was treated with atorvastatin calcium tablets, while the observation group was administered with evolocumab in addition to the control group's regimen. The blood lipid levels, carotid intima-media thickness (CIMT), plaque thickness, serum amyloid A1 (SAA1), cerebral blood volume (CBV) and cerebral blood flow (CBF) before and after treatment, as well as the incidence of adverse reactions during medication were compared between the two groups. The incidence of adverse endpoint events such as recurrent cerebral infarction, restenosis and death within 1 year after treatment was recorded. 【Results】 After treatment, the blood lipid metabolism level in the observation group was significantly improved compared with that in the control group. The levels of CIMT, plaque thickness and serum SAA1 in the observation group were lower than those in the control group, while CBV and CBF were higher than those in the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). The incidence of adverse endpoint events in the observation group was lower than that in the control group (P<0.05). 【Conclusion】 Evolocumab combined with atorvastatin can more effectively improve the blood lipid profile, carotid artery lesions and cerebral blood flow status of patients with symptomatic ICAS safely. It reduces the incidence of adverse endpoint events.
|
|
Received: 23 October 2025
|
|
|
|
|
|
[1] 蒋兰,孙梦飞,李怡萍,等. PCSK9抑制剂在症状性颅内动脉粥样硬化狭窄患者早期强化降脂治疗的作用[J].临床神经病学杂志,2024,37(5):350-355.
[2] 李卫征,武国良,吴强. 依达拉奉右莰醇与阿托伐他汀对老年急性脑梗死伴颅内动脉狭窄患者脂代谢及炎症影响[J].中华老年心脑血管病杂志,2023,25(1):57-61.
[3] 张静,芦亚兰,何勐,等. 依洛尤单抗联合瑞舒伐他汀治疗急性冠状动脉综合征的临床研究[J].中国合理用药探索,2024,21(8):79-85.
[4] SAMULS O B, JOSEPH G J, LYNN M J,et al. A standardized method for measuring intracranial arterial stenosis[J].AJNR Am J Neuroradiol,2000, 21(4):643-646.
[5] 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中. 中国急性缺血性脑卒中诊治指南2010[J].中国全科医学,2011,14(35):4013-4017.
[6] 王伊龙,陈玮琪,刘欣如,等. 中国脑血管病临床管理指南(第2版)(节选):第3章脑血管病高危人群管理[J].中国卒中杂志,2023,18(8):898-909.
[7] 高鹏,王志飞. 中国颅内动脉粥样硬化性狭窄介入治疗的现状与未来[J].中国脑血管病杂志,2023,20(5):289-297.
[8] JADHAV S B, CRASS R L, CHAPEL S,et al. Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model[J].Eur Heart J Card Pharmacother,2022, 8(6):578-586.
[9] LEHRKE M, VOGT A, SCHETTLER V, et al. Evolocumab-based LDL-C management in high and very high cardiovascular risk patients in german clinical practice: the HEYMANS study[J].Adv Ther,2024, 41(3):1184-1200.
[10] 刘惠,蒋萌,束宁德,等. 针对动脉粥样硬化性心脑血管疾病的新型降脂药物的作用机制及研究进展[J].中国医学创新,2024,21(5):157-164.
[11] DI FUSCO S A, ARCA M, SCICCHITANO P,et al. Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target[J].Heart,2022,109(1):18-25.
[12] GERMAN C A, LIAO J K. Understanding the molecular mechanisms of statin pleiotropic effects[J].Arch Toxicol,2023, 97(6):1529-1545.
[13] 吴小燕,肖凯,文晓柯,等. 新型降脂药物PCSK9抑制剂临床疗效研究进展[J].中国医药导刊,2024,26(3):231-235.
[14] JIA X, LIU Z T, WANG Y X,et al. Serum amyloid A and interleukin -1β facilitate LDL transcytosis across endothelial cells and atherosclerosis via NF-κB/caveolin-1/cavin-1 pathway[J].Atherosclerosis,2023, 375(1):87-97.
[15] 路怀志,赵辉,王勇,等. 前蛋白转化酶枯草溶菌素9抑制剂作为一级预防治疗对兔动脉粥样硬化斑块发生与进展的影响[J].中国医药,2024,19(8):1137-1141. |
|
|
|
2026, Vol. 43 
